Full-Time

Operations Technician 2

Posted on 10/7/2025

LFB

LFB

1,001-5,000 employees

Public health biopharmaceuticals via plasma-derived products

No salary listed

Webster, MA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Technical skills to include IM, IV, SC, and IP injections, and IV blood collection procedures
  • Have an understanding of applicable Quality Systems (e.g. change control, deviations)
  • Demonstrate the ability to work on assigned projects independently with little or no supervision
  • Identify safety issues and initiate corrective actions to reach resolution
  • Exhibit a sound understanding of applicable animal care and use guidelines
Responsibilities
  • Daily animal care activities to include: feeding, animal observations/identification of clinical concerns, and nail trimming
  • Husbandry activities to include cage change/cleaning, use of power wash and chemical dispensing equipment, and general facility sanitization and support
  • Milking of rabbits and standard support activities to meet production goals and adherence to established schedules
  • Proper restraint of rabbits to facilitate general animal care, transfers, sample collection, and advanced handling (AI restraint)
  • Assess animals, initiate veterinary care and execute animal treatments
  • Perform animal identification applications to include ear tags, tattoos and RFID transponders
  • May perform and provide support, to include updating of records, for natural and artificial insemination breeding procedures, pregnancy palpation and kindling/weaning procedures
  • Utilize computer and paper based systems to accurately document and/or record information to assure compliance with applicable regulations, and company policies
  • May write, modify, and provide training (as assigned) on SOPs/WI/TM
  • Identify and communicate animal welfare concerns
  • Weekend and holiday coverage required on a rotating basis

LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Courcebœufs, France

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • ESCAPE strategy doubles bioproduction capacity by 2025.
  • Amber Plasma acquisition boosts Czech centers to 24.
  • Arras site triples medication production for patient demand.

What critics are saying

  • FDA bans cripple LFB USA rPRO™ proteins in 12-18 months.
  • CSL Behring squeezes Europlasma's 24 centers in 6-12 months.
  • Grifols captures 25% hemostasis share in 12-24 months.

What makes LFB unique

  • LFB specializes in plasma-derived medicines from 1994 French state initiative.
  • rPRO™ technology expresses recombinant proteins in transgenic animal milk.
  • Europlasma secures plasma via 24 Central European collection centers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Education allowance

Tuition Reimbursement

Company News

MyPharma Editions
May 30th, 2024
LFB Acquires Amber Plasma in Czech Republic

Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.

INACTIVE